Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.78 |
| ▸ | HTR2C | P28335 | 3/20 | 0.78 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583840 | 0.88 | HTR2A (1.00) | HTR2AKCNH2HTR2CDRD2GRIN1 | |
| SCHEMBL4874296 | 0.82 | ALDH1A1 (0.71) | ALDH1A1KDRGAAMAPK1 | |
| SCHEMBL10730073 | 0.77 | ACHE (0.70) | DRD2ALDH1A1GAA | |
| SCHEMBL15340905 | 0.76 | KMT2A (0.64) | ALDH1A1KDRGAAMAPK1 | |
| SCHEMBL6585664 | 0.76 | HTR2A (0.78) | HTR2AKCNH2HTR2CDRD2ALDH1A1 | |
| SCHEMBL21748552 | 0.76 | KMT2A (0.51) | DRD2ALDH1A1KDRGAAMAPK1 | |
| SCHEMBL21748573 | 0.74 | ALDH1A1 (0.57) | DRD2ALDH1A1 | |
| SCHEMBL8299032 | 0.74 | ALDH1A1 (0.48) | GRIN2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL4485907 | 0.73 | ALDH1A1 (0.80) | KCNH2DRD2GRIN2BALDH1A1KDR | |
| SCHEMBL1806612 | 0.73 | CA12 (0.62) | HSD11B1ALDH1A1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147084-B1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME (GB) | 2004-05-19 | — | — | EP | claimed |
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | MERCK & CO., INC. | 2003-10-30 | — | — | US | claimed |
| US-6559166-B1 | A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore | MERCK SHARP & DOHME LTD. | 2003-05-06 | — | — | US | claimed |
| EP-1147084-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-24 | — | — | EP | claimed |
| WO-2000043362-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-07-27 | — | — | WO | claimed |
| US-6777430-B2 | A DERIVATIVES WITH ATTACHED TO AN N-ARYLALKYL-SUBSTITUTED AZETIDINE, PYRROLIDINE OR PIPERIDINE RING; A SERATONIN RECEPTOR ANTAGONISTS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER SCHIZOPHRENIA, DEPRESSION | MERCK SHARP & DOHME LTD. | 2004-08-17 | — | — | US | disclosed |
| EP-1147084-B1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME (GB) | 2004-05-19 | — | — | EP | disclosed |
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | MERCK & CO., INC. | 2003-10-30 | — | — | US | disclosed |
| US-6559166-B1 | A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore | MERCK SHARP & DOHME LTD. | 2003-05-06 | — | — | US | disclosed |
| EP-1147084-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043362-A1 | PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203889-A1 | Phenylsulphonyl derivatives as 5-HT receptor ligands | HTR2A, HTR5A, HTR2C | HTR2A 1/4885KCNH2 461/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.